Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Evoke flags 5pc rise in second-quarter revenue

(Sharecast News) - Evoke said on Tuesday that second-quarter revenue rose by 5% year-on-year, driven by growth in online betting and gaming and a recovery in retail following the rollout of 5,000 new gaming machines earlier this year. In a post-close trading update for the three and six months ended 30 June, the William Hill parent formerly known as 888 Holdings said online revenue rose around 6% in the second quarter, with continued strength in international core markets.

Retail returned to growth following machine upgrades completed in March, while sports betting performance was affected by a tough comparative period, which included the Euros and a stronger win margin last year.

Group revenue for the first half rose by 3%, with double-digit growth in gaming offsetting sports weakness.

Evoke said it expected adjusted EBITDA for the half to come in between £163m and £167m, up 43% at the midpoint compared with the same period last year.

That would lift last 12-month EBITDA to over £360m, and support ongoing deleveraging efforts.

"The second quarter of 2025 marked our second strongest quarterly revenue performance since the beginning of 2023, a particularly encouraging result given the tough comparator from lapping the Euros," said chief executive Per Widerström.

"Importantly, this growth was also delivered profitably, in line with our focus on sustainable profitable growth."

He added that the company continued to transform the group's capabilities for the mid- and long-term.

"Our disciplined strategy with clear focus on our core markets and driving operational excellence is delivering improved profitability and enabling further deleveraging."

Evoke reaffirmed its full-year guidance for 5% to 9% revenue growth and an adjusted EBITDA margin of at least 20%.

The company said it would report its interim results on 13 August.

At 1108 BST, shares in Evoke were up 4.88% at 64.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.